facebook digital coin Top Top stories

According to the key industrial fields mentioned in the action plan, Shanghai's local semiconductor leading enterprises, pharmaceutical leading enterprises and new material leading enterprises are also expected to benefit from the merger and acquisition plan.In the secondary market, the concept stocks of M&A and restructuring rose strongly, and the restructuring index rose nearly 63% since September 24th.After the market, there was a big profit. The General Office of the Shanghai Municipal People's Government issued a notice on printing and distributing the Action Plan of Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027).

[The time is ripe for Shanghai stocks to become monsters in batches! 】From the perspective of institutional attention, Zhongwei Company and Weir Co., Ltd. have more than 30 institutional ratings, while Hengxuan Technology, Lanqi Technology, UIH Medical and Microelectrophysiology -U have more than 20 institutional ratings.Zhongwei company is a company engaged in the research, development, production and sales of high-end semiconductor equipment and pan-semiconductor equipment. Great Wall Securities said that the company's etching, thin film deposition and MOCVD equipment have reached the international advanced level.

In addition, the market value of Zhongwei Company, Weir Shares and UIH Medical all exceeded 100 billion yuan.Shanghai state-owned companies are expected to directly benefit from the action plan. According to the statistics of Securities Times and Data Treasure, there are 37 A-shares owned by Shanghai State-owned Assets with a market value of less than 10 billion yuan. Among them, the market value of Kaikai Industrial, Chuangchuang International, First Pharmaceutical and other stocks is less than 3 billion yuan, and the market value of Yatong, Changjiang Investment, Changlian, Shanghai Jiubai and *ST Tianwo is less than 4 billion yuan.The stagflation stocks mainly include Haohaishengke, Shanghai Laishi and Weir. Among them, Haohai Shengke increased by less than 10%. The company is a scientific and technological innovative enterprise that applies biomedical materials technology and genetic engineering technology to research, develop, produce and sell medical devices and drugs. It is committed to providing innovative medical products for the market through technological innovation and transformation, integration of domestic and foreign resources and large-scale production, and gradually realizing the import substitution of related medical products, thus becoming a leading enterprise in the field of biomedical materials.